Mitral stenosis screening: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:
According to the  2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]".
According to the  2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]".
==Screening==
==Screening==
According to the  2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]".<ref name="NishimuraOtto2014">{{cite journal|last1=Nishimura|first1=Rick A.|last2=Otto|first2=Catherine M.|last3=Bonow|first3=Robert O.|last4=Carabello|first4=Blase A.|last5=Erwin|first5=John P.|last6=Guyton|first6=Robert A.|last7=O’Gara|first7=Patrick T.|last8=Ruiz|first8=Carlos E.|last9=Skubas|first9=Nikolaos J.|last10=Sorajja|first10=Paul|last11=Sundt|first11=Thoralf M.|last12=Thomas|first12=James D.|title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary|journal=Circulation|volume=129|issue=23|year=2014|pages=2440–2492|issn=0009-7322|doi=10.1161/CIR.0000000000000029}}</ref>
According to the  2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]".<ref name="NishimuraOtto2014">{{cite journal|last1=Nishimura|first1=Rick A.|last2=Otto|first2=Catherine M.|last3=Bonow|first3=Robert O.|last4=Carabello|first4=Blase A.|last5=Erwin|first5=John P.|last6=Guyton|first6=Robert A.|last7=O’Gara|first7=Patrick T.|last8=Ruiz|first8=Carlos E.|last9=Skubas|first9=Nikolaos J.|last10=Sorajja|first10=Paul|last11=Sundt|first11=Thoralf M.|last12=Thomas|first12=James D.|title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary|journal=Circulation|volume=129|issue=23|year=2014|pages=2440–2492|issn=0009-7322|doi=10.1161/CIR.0000000000000029}}</ref><ref name="NishimuraOtto2017">{{cite journal|last1=Nishimura|first1=Rick A.|last2=Otto|first2=Catherine M.|last3=Bonow|first3=Robert O.|last4=Carabello|first4=Blase A.|last5=Erwin|first5=John P.|last6=Fleisher|first6=Lee A.|last7=Jneid|first7=Hani|last8=Mack|first8=Michael J.|last9=McLeod|first9=Christopher J.|last10=O’Gara|first10=Patrick T.|last11=Rigolin|first11=Vera H.|last12=Sundt|first12=Thoralf M.|last13=Thompson|first13=Annemarie|title=2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines|journal=Circulation|volume=135|issue=25|year=2017|issn=0009-7322|doi=10.1161/CIR.0000000000000503}}</ref>


==References==
==References==

Revision as of 20:21, 10 March 2020

Mitral Stenosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Mitral Stenosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Stages

History and Symptoms

Physical Examination

Electrocardiogram

Chest X Ray

Echocardiography

Cardiac MRI

Cardiac Catheterization

Treatment

Overview

Medical Therapy

Percutaneous Mitral Balloon Commissurotomy (PMBC)

Surgery

Follow Up

Prevention

Case Studies

Case #1

Mitral stenosis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mitral stenosis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onMitral stenosis screening

CDC on Mitral stenosis screening

Mitral stenosis screening in the news

Blogs on Mitral stenosis screening

Directions to Hospitals Treating Mitral Stenosis

Risk calculators and risk factors for Mitral stenosis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

According to the 2014 and 2017 AHA/ACC Guideline, screening for mitral stenosis by TTE is recommended among patients with signs or symptoms. " Exercise testing with Doppler or invasive hemodynamic assessment is recommended to evaluate the response of the mean mitral gradient and pulmonary artery pressure in patients with MS when there is a discrepancy between resting Doppler echocardiographic findings and clinical symptoms or signs".

Screening

According to the 2014 and 2017 AHA/ACC Guideline, screening for mitral stenosis by TTE is recommended among patients with signs or symptoms. " Exercise testing with Doppler or invasive hemodynamic assessment is recommended to evaluate the response of the mean mitral gradient and pulmonary artery pressure in patients with MS when there is a discrepancy between resting Doppler echocardiographic findings and clinical symptoms or signs".[1][2]

References

  1. Nishimura, Rick A.; Otto, Catherine M.; Bonow, Robert O.; Carabello, Blase A.; Erwin, John P.; Guyton, Robert A.; O’Gara, Patrick T.; Ruiz, Carlos E.; Skubas, Nikolaos J.; Sorajja, Paul; Sundt, Thoralf M.; Thomas, James D. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Circulation. 129 (23): 2440–2492. doi:10.1161/CIR.0000000000000029. ISSN 0009-7322.
  2. Nishimura, Rick A.; Otto, Catherine M.; Bonow, Robert O.; Carabello, Blase A.; Erwin, John P.; Fleisher, Lee A.; Jneid, Hani; Mack, Michael J.; McLeod, Christopher J.; O’Gara, Patrick T.; Rigolin, Vera H.; Sundt, Thoralf M.; Thompson, Annemarie (2017). "2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 135 (25). doi:10.1161/CIR.0000000000000503. ISSN 0009-7322.

Template:WH Template:WS